Publications by authors named "G M Dusheiko"
The surety or otherwise of leaving chronic hepatitis B untreated.
Lancet Gastroenterol Hepatol
December 2024
Article Synopsis
- The introduction of direct-acting antivirals (DAAs) offers hope for eliminating hepatitis C virus (HCV) by 2030, but some patients (2%-12%) experience treatment failure, potentially due to existing drug resistance.
- A systematic review of 56 studies found a high prevalence of hepatitis C resistance-associated substitutions (RAS) among patients with virological failure after DAA treatment, ranging from 78% to 100% depending on the specific treatment regimen.
- The findings highlight the importance of monitoring DAA-associated resistance and understanding its implications for future treatment strategies.
HBV eradication from the host: Current understanding and challenges.
Clin Liver Dis (Hoboken)
June 2024
Article Synopsis
- What is the main idea or topic of the text?
- What are some important details or events?
- What is the conclusion or final thought of the text? Once you provide that, I can help you summarize it!
Article Synopsis
- Chronic hepatitis B infection (CHB) affects 300 million people and is part of a global effort by the United Nations and WHO to eliminate it as a health threat by 2030.
- Peer support workers (PSWs) are people who have experienced similar health issues and can help others by providing education and emotional support, especially for those with CHB.
- Investing in peer support can help improve healthcare access, reduce stigma, and ultimately contribute to the goal of eliminating hepatitis B around the world.
Background: As new therapeutic options become available, better understanding the potential impact of emerging therapies on clinical outcomes of hepatits D virus (HDV) is critical.
Objective: The aim of this study was to develop a natural history model for patients with hepatitis D virus.
Methods: We developed a model (decision tree followed by a Markov cohort model) in adults with chronic HDV infection to assess the natural history and impact of novel treatments on disease progression versus best supportive care (BSC).